Natco Pharma Vizag facility begins production

The Visakhapatnam facility was a part of the Special Economic Zone (SEZ) and intended to cater primarily to the U.S. and other international markets, Natco Pharma said.

Hyderabad: Natco Pharma Limited on Thursday announced the commencement of commercial operations by its Finished Dosage Formulations (FDF) facility in Visakhapatnam, which is a key part of its capacity expansion plans.

The facility was a part of the Special Economic Zone (SEZ) and intended to cater primarily to the U.S. and other international markets, a company release here said.

The Vizag facility is a key part of Natco's capacity expansion plans for its pipeline of products and diversification into different geographies.

Read Also: Natco Pharma Q2 profit declines to Rs 118 crore due to a drop in oseltamivir product sales in the US

From the capability perspective, this facility will focus mostly on oral solid dosages (tablets and capsules), including a cytotoxic block for products in the oncology segment, the city-based drugmaker said.

An application with the U.S. Food and Drug Administration (USFDA) is already filed for site transfer of the first product and for a regulatory audit, it added.

Read Also: Natco Pharma Mekaguda facility gets EIR from USFDA